Imidapril
As of the edition of 20 October 2026, Imidapril is a small molecule: marketed, first approved in 2000 (ES); acts on ACE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Hipertene
- First approved
- 31 October 2000 (ES)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Laboratorios Bial S.A.
- Registered trials
- 2, 0 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACE | Angiotensin-converting enzyme | P12821 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 0 | 0 | 0 |
| All trials | 2 |